Understanding idiopathic generalized epilepsy syndromes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on idiopathic generalized epilepsies (IGEs), including childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, and generalized tonic-clonic seizures. It aims to describe the clinical features, electroencephalographic findings, imaging results, and long-term prognosis of patients diagnosed with IGEs. By collecting comprehensive clinical information and conducting 24-hour video-electroencephalography, the study seeks to inform optimal treatment strategies and improve patient outcomes. The findings will also address the rates of drug-resistant epilepsy and common comorbidities associated with these syndromes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients are consecutively and prospectively enrolled from epilepsy center, with newly diagnosed epilepsy or established epilepsy.
* Patients have a diagnosis of idiopathic generalized epilepsy (IGE), according to the 2022 diagnostic criteria.
* Comprehensive clinical information is collected, and 24 hour video-electroencephalography is performed.
* Sign the informed consent forms.

Exclusion Criteria:

* Other epilepsy syndromes are considered during follow-up, such as genetic generalized epilepsy.
* Lost to follow-up

Where it's running

• 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Principal investigator: Chunhong Shen — Second Affiliated Hospital, Zhejiang University, School of Medicine
• Study coordinator: Chunhong Shen
• Email: shen_neurology@zju.edu.cn
• Phone: +86 0571 87783872

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• RAP-219 long-acting injectable safety and PK study in healthy adults

  This early study tests RAP-219-LAI in healthy adults to see how it behaves in the body and whether it is safe and tolerable.

  Recruiting Phase 1 Rapport Therapeutics Inc. · Adelaide · NCT07923097

• Why People with Epilepsy Get More Infections

  This study tests whether anti-seizure medicines affect immune function and infection risk in people with epilepsy.

  Recruiting University of Aberdeen · Aberdeen · NCT07903168

• Long-Term Epilepsy Outcomes in Children After Perinatal Stroke

  This study looks at how epilepsy progresses in kids who had a stroke before 28 days old to see how their seizures and syndromes evolve over time.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07898397

• Hypothalamus structure and heart autonomic changes in drug-resistant epilepsy

  This study tests whether structural changes in the hypothalamus relate to cardiac autonomic dysfunction in adults with drug-resistant epilepsy.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Picardie · NCT07888543

• One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions

  A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.

  Recruiting Brigham and Women's Hospital · Boston, Massachusetts · NCT07883720

• Advanced 7T fMRI for brain function in epilepsy and brain injuries

  This study tests ultra-high-field brain scans at 7T to see if they can better map brain function in adults with epilepsy or brain lesions and in healthy volunteers.

  Recruiting Imago 7 Fondazione di Ricerca onlus · Pisa, Italy · NCT07865546

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.